• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer.老年转移性结肠癌患者的当前治疗策略
Cureus. 2019 May 22;11(5):e4713. doi: 10.7759/cureus.4713.
2
Current treatment strategies in elderly patients with metastatic colorectal cancer.
Clin Colorectal Cancer. 2007 May;6(7):508-15. doi: 10.3816/ccc.2007.n.016.
3
First-line treatment strategies for elderly patients with metastatic colorectal cancer.老年转移性结直肠癌患者的一线治疗策略
Drugs Aging. 2007;24(3):223-38. doi: 10.2165/00002512-200724030-00004.
4
Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis.辅助化疗持续时间与 II 期和 III 期结肠癌患者生存的关系:系统评价和荟萃分析。
JAMA Netw Open. 2019 May 3;2(5):e194154. doi: 10.1001/jamanetworkopen.2019.4154.
5
Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.辅助化疗与 III 期结肠癌老年患者胃肠道、血液学和心脏毒性的风险。
Am J Clin Oncol. 2012 Jun;35(3):228-36. doi: 10.1097/COC.0b013e318210f812.
6
Obesity: What is an elderly population growing into?肥胖:老年人口正走向何种境地?
Maturitas. 2009 May 20;63(1):7-12. doi: 10.1016/j.maturitas.2009.02.010. Epub 2009 Mar 27.
7
Agreement between Medline searches using the Medline-CD-Rom and Internet Pubmed, BioMedNet, Medscape and Gateway search-engines.使用Medline光盘版与互联网上的PubMed、BioMedNet、Medscape及网关搜索引擎进行Medline检索之间的一致性。
Rev Salud Publica (Bogota). 2005 May-Aug;7(2):214-26. doi: 10.1590/s0124-00642005000200009.
8
9
Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.检测炎症性肠病患者结肠癌和/或发育异常的策略。
Cochrane Database Syst Rev. 2006 Apr 19(2):CD000279. doi: 10.1002/14651858.CD000279.pub3.
10
Systematic review of management of colorectal cancer in elderly patients.老年结直肠癌管理的系统评价
Clin Colorectal Cancer. 2003 Nov;3(3):165-71. doi: 10.3816/CCC.2003.n.022.

引用本文的文献

1
The increasing prevalence of cancer in the elderly: An investigation of epidemiological trends.老年人癌症患病率的上升:流行病学趋势调查
Aging Med (Milton). 2024 Aug 18;7(4):516-527. doi: 10.1002/agm2.12347. eCollection 2024 Aug.
2
The Antagonistic and Synergistic Role of Fe Compounds in Chemo- and Electrochemotherapy in Human Colon Cancer In Vitro.铁化合物在人结肠癌体外化疗和电化学疗法中的拮抗和协同作用
Pharmaceuticals (Basel). 2024 May 17;17(5):651. doi: 10.3390/ph17050651.
3
Construction and validation of a chemokine family-based signature for the prediction of prognosis and therapeutic response in colon cancer.用于预测结肠癌预后和治疗反应的基于趋化因子家族的特征构建与验证
Heliyon. 2023 Jun 5;9(6):e16478. doi: 10.1016/j.heliyon.2023.e16478. eCollection 2023 Jun.
4
Adjuvant chemotherapy improves survival in high-risk stage II colon cancer: a retrospective cohort study.辅助化疗可提高高危II期结肠癌患者的生存率:一项回顾性队列研究。
Therap Adv Gastroenterol. 2022 Nov 21;15:17562848221137758. doi: 10.1177/17562848221137758. eCollection 2022.
5
Cytotoxic potentials of silibinin assisted silver nanoparticles on human colorectal HT-29 cancer cells.水飞蓟宾辅助银纳米颗粒对人结肠HT-29癌细胞的细胞毒性潜力。
Bioinformation. 2020 Nov 30;16(11):817-827. doi: 10.6026/97320630016817. eCollection 2020.
6
Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment.结肠癌治疗中5-氟尿嘧啶耐药机制及逆转策略的最新进展
Biology (Basel). 2021 Aug 31;10(9):854. doi: 10.3390/biology10090854.

本文引用的文献

1
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.三期 RECOURSE 试验的亚组分析,比较替拉鲁肽/曲氟尿苷(TAS-102)联合最佳支持治疗与安慰剂联合最佳支持治疗用于转移性结直肠癌患者。
Eur J Cancer. 2018 Feb;90:63-72. doi: 10.1016/j.ejca.2017.10.009. Epub 2017 Dec 21.
2
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.FOLFIRI与西妥昔单抗用于老年转移性结直肠癌患者的一线治疗:CAPRI-GOIM试验中的临床活性与耐受性
ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016.
3
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.西妥昔单抗治疗转移性结直肠癌:北欧-VII研究的最终生存分析及扩展的RAS数据
Br J Cancer. 2017 May 9;116(10):1271-1278. doi: 10.1038/bjc.2017.93. Epub 2017 Apr 11.
4
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.临床实践中≥75岁转移性结直肠癌患者的治疗:一项多中心分析
PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016.
5
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.阿柏西普联合氟尿嘧啶、亚叶酸钙和伊立替康治疗既往治疗的转移性结直肠癌:VELOUR 试验的预先指定亚组分析。
Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16.
6
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.贝伐珠单抗联合卡培他滨对比卡培他滨单药治疗未经治疗的转移性结直肠癌老年患者(AVEX):一项开放标签、随机、3 期临床试验。
Lancet Oncol. 2013 Oct;14(11):1077-1085. doi: 10.1016/S1470-2045(13)70154-2. Epub 2013 Sep 10.
7
Contraindicated use of bevacizumab and toxicity in elderly patients with cancer.不建议在老年癌症患者中使用贝伐珠单抗和(发生)毒性。
J Clin Oncol. 2013 Oct 1;31(28):3592-9. doi: 10.1200/JCO.2012.48.4857. Epub 2013 Sep 3.
8
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.regorafenib 单药治疗既往治疗的转移性结直肠癌(CORRECT):一项国际、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
9
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.老年和虚弱型转移性结直肠癌(MRC FOCUS2)患者的化疗选择:一项开放标签、随机分组的析因试验。
Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11.
10
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.一项比较伊立替康、亚叶酸钙和氟尿嘧啶与亚叶酸钙和氟尿嘧啶辅助化疗用于 II 期和 III 期结肠癌的随机 III 期试验:希腊肿瘤协作组研究。
BMC Med. 2011 Jan 31;9:10. doi: 10.1186/1741-7015-9-10.

老年转移性结肠癌患者的当前治疗策略

Current Treatment Strategies for Elderly Patients with Metastatic Colon Cancer.

作者信息

Idrees Muhammad, Tejani Mohamed

机构信息

Internal Medicine, Bassett Medical Center - Columbia University, Cooperstown, USA.

Oncology, University of Rochester, Rochester, USA.

出版信息

Cureus. 2019 May 22;11(5):e4713. doi: 10.7759/cureus.4713.

DOI:10.7759/cureus.4713
PMID:31355073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6650188/
Abstract

Colon cancer is one of the most common cancers in the United States and is expected to rise as the prevalence of colon cancer is increasing with increasing aging population. Though some studies have shown benefits of chemotherapy in the elderly population, however, they are also at risk of drug toxicities. We searched major search engines including PubMed, Medline and EMBASE and reviewed articles published in the last 10 years. Here we present current treatment strategies available for the metastatic colon cancer in elderly patients.

摘要

结肠癌是美国最常见的癌症之一,并且随着老年人口的增加,结肠癌患病率上升,预计其发病率也会上升。尽管一些研究表明化疗对老年人群有益,然而,他们也有药物毒性的风险。我们检索了包括PubMed、Medline和EMBASE在内的主要搜索引擎,并回顾了过去10年发表的文章。在此,我们介绍老年转移性结肠癌患者目前可用的治疗策略。